

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6107726

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WILLIAM WINSTON	05/04/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	WEREWOLF THERAPEUTICS, INC.
<b>Street Address:</b>	1030 MASSACHUSETTS AVENUE
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02138
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	US2019032320
<b>PCT Number:</b>	US2019032321
<b>PCT Number:</b>	US2019032322
<b>Application Number:</b>	62847914
<b>Application Number:</b>	16438156
<b>Application Number:</b>	16438166
<b>Application Number:</b>	62938786
<b>Application Number:</b>	62935605
<b>Application Number:</b>	62938685
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)371-1037
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-371-1019
<b>Email:</b>	catherine.heath@hoganlovells.com
<b>Correspondent Name:</b>	ROBERT H. UNDERWOOD
<b>Address Line 1:</b>	HOGAN LOVELLS US LLP
<b>Address Line 2:</b>	125 HIGH STREET, SUITE 2010
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>NAME OF SUBMITTER:</b>	RHIANNA LINDOP
<b>SIGNATURE:</b>	/Rhianna Lindop/

PATENT

<b>DATE SIGNED:</b>	05/14/2020
<b>Total Attachments: 4</b> source=2020.05.13_Executed William Winston Assignment (761146.000001)#page1.tif source=2020.05.13_Executed William Winston Assignment (761146.000001)#page2.tif source=2020.05.13_Executed William Winston Assignment (761146.000001)#page3.tif source=2020.05.13_Executed William Winston Assignment (761146.000001)#page4.tif	

Atty. Docket. Nos. 761146-000020/000021/000022/000023/000026/000027/000133/000134/0000135

**ASSIGNMENT**

WHEREAS, I, **William Winston**, (hereinafter referred to as “Assignor”) have made certain new and useful inventions described and/or claimed in the patent applications as set forth in **Schedule A** attached hereto and incorporated herein by reference;

AND WHEREAS, **Werewolf Therapeutics, Inc.**, a corporation organized and existing under the laws of Delaware, and having a usual place of business at **1030 Massachusetts Avenue, Cambridge, Massachusetts 02138** (hereinafter referred to as “Assignee”), is desirous of acquiring the entire right, title and interest in and to said inventions and in and to any and all Letters Patent of the United States and foreign countries which may be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged we do hereby sell, assign, transfer and set over unto Assignee, its lawful successors and assigns, our entire right, title and interest in and to said inventions, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) any PCT International Application and all national stage applications based thereon, all divisions, continuations, continuations-in-part, reissues, reexaminations and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement, treaties and laws; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors

Atty. Docket. Nos. 761146-000020/000021/000022/000023/000026/000027/000133/000134/0000135

and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **Hogan Lovells US LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.


ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **Hogan Lovells US LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

Joint Invention  
Worldwide Rights

Atty. Docket. Nos. 761146-000020/000021/000022/000023/000026/000027/000133/000134/0000135

IN TESTIMONY WHEREOF, we have hereunto set our hands.

ASSIGNOR (Inventor 1)



Signature

William Winston


Print Name

5/4/2020

Execution Date

Acknowledged and Accepted by:

Werewolf Therapeutics, Inc.



Print Name:

DAN HICKLIN

Print Title:

President & CEO

Date:

12 MAY 2020

Joint Invention  
Worldwide Rights

Atty. Docket. Nos. 761146-000020/000021/000022/000023/000026/000027/000133/000134/0000135

**SCHEDULE A**

<b>Attorney Docket No.</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Title</b>
761146.000020	PCT/US2019/032320	May 14, 2019	ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS THEREOF
761146.000021	PCT/US2019/032321	May 14, 2019	ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
761146.000022	PCT/US2019/032322	May 14, 2019	ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
761146.000023	62/847,914	May 14, 2019	SEPARATION MOIETIES AND METHODS OF USE THEREOF
761146.000026	16/438,156	June 11, 2019	ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES
761146.000027	16/438,166	June 11, 2019	ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES
761146.000133	62/938,786	November 21, 2019	SEPARATION MOIETIES AND METHODS OF USE THEREOF
761146.000134	62/935,605	November 14, 2019	ACTIVATABLE CYTOKINE POLYPEPTIDE AND METHODS THEREOF
761146.000135	62/938,685	November 21, 2019	PROTEASE INHIBITORS AND METHODS OF USE THEREOF